[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631052":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":25,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":10,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Severe Psoriasis Cohort",null,"patients with severe chronic plaque psoriasis receiving systemic treatment (conventional or biologic therapy) as part of their routine clinical care. Participants undergo clinical evaluation (PASI, BSA), dermoscopic imaging, and complete Psoriasis Disability Index (PDI) and Dermatology Life Quality Index (DLQI) questionnaires at baseline and at 3 and 6 months following treatment initiation. No experimental interventions are administered; patients receive standard prescribed treatment per their dermatologist's clinical judgment.",[13],{"name":14,"affiliation":5,"role":15},"Alaa W Ibrahim, Resident","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+2001090130838","dralaawalid310@gmail.com",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Islam A Mahmoud, Resident","+2001129198914","Islam.16266328@med.aun.edu.eg",{"type":15,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Alaa Walid Ibrahim Sultan","Resident","100631052","pre-post-multimodal-assessment-of-severe-psoriasis-vulgaris-using-clinical-dermoscopic-and-qol-measures-100631052",false,"NCT07495657","Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures","Multimodal Evaluation of Severe Psoriasis Vulgaris Before and After Treatment Using Clinical, Dermoscopic, Psoriasis Disability Index, and Quality of Life Parameters","Inclusion Criteria:\n\n* Patients ≥ 6 years of age\n\n  * Newly diagnosed patients with plaque psoriasis with affected BSA \\>10%\n  * Indicated for a new systemic therapy (e.g., oral agent, biologics).\n  * Willing and able to provide informed consent for all procedures .\n  * At least one eligible, representative target plaque for serial dermoscopic imaging .\n  * Stop previous systemic therapy at least 2-3 months\n\nExclusion Criteria:\n\n* • Non cooperative patients .\n\n  * Pregnant or breastfeeding women","ALL","6 Years",{"count":38,"type":39},45,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the comprehensive changes in severe plaque psoriasis (Psoriasis Vulgaris) in adult participants undergoing standard treatment. The main questions it aims to answer are: How clinical signs of psoriasis, such as redness, scaling, and thickness, change after treatment? How specific skin features, visualized under dermoscopy, change after treatment? How participants' perceptions of psoriasis-related disability and overall quality of life improve after treatment? Participants will undergo standard medical treatment for severe psoriasis. Participants will be evaluated at the beginning of the study and again after treatment using clinical skin examinations, dermoscopic imaging, and validated questionnaires (Psoriasis Disability Index and quality of life parameters).",[43],"Psoriasis Vulgaris","NOT_YET_RECRUITING","2026-03-24",{"date":47,"type":48},"2026-03-27","ACTUAL",{"date":50,"type":39},"2026-05-01",{"date":52,"type":39},"2027-11-01",{"name":5,"class":6}]